Filing step-change
VIVOBIOT · 2026-09
Quarterly observations that moved versus the prior period in 2026-09. Facts only — not a call to act.
Narrative date 2026-09-28 · Evidence medium
Vivo Biotech Sees Strong Quarterly Performance Vivo Biotech (VIVOBIOT) reported a significant acceleration in its gross margin, rising to 84.62% in the latest quarter, a substantial improvement from 10.65% in the previous period.
Raw Evidence
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 84.62 % | 10.65 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 10.65 % | -5.19 | ▲ |
| REVENUE_GROWTH_YOY | 14.1 % | -89.2 | ▲ |
Cite this
Source: Samhati filing step-change for VIVOBIOT (2026-09). Observation: Vivo Biotech Sees Strong Quarterly Performance Vivo Biotech (VIVOBIOT) reported a significant acceleration in its gross margin, rising to 84.62% in the latest quarter, a substantial improvement from 10.65% in the previous period. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/vivobiot/q/2026-09
Other periods